The importance of correct management in a 15-year-old boy with severe pulmonary arterial hypertension associated with patent ductus arteriosus
Main Article Content
Keywords
pulmonary arterial hypertension, congenital heart disease, patent ductus arteriosus, AVT, selective pulmonary vasodilator
Abstract
Background: Pulmonary arterial hypertension (PAH) is a condition in which pulmonary vascular pressure increases and is associated with diverse diseases or aetiologies. In children, 50% of PAH cases are caused by congenital heart disease (CHD), especially due to large left-to-right shunts. Large systemic to pulmonary shunts may develop in PAH if left untreated or repaired late. PAH, when present, markedly increases morbidity and mortality in patients with CHD.
Case presentation: We present a 15-year-old boy with a large patent ductus arteriosus (PDA) and severe pulmonary arterial hypertension. Catheterization under general anaesthesia was performed at the age of 16 years. We performed an acute vasoreactivity test (AVT), with the AVT result showing pulmonary arterial hypertension with high flow and low resistance. Transcatheter closure (TCC) of PDA was performed, resulting in no residual PDA. Meanwhile, the echocardiographic finding showed that there was still class II pulmonary arterial hypertension. We then gave heart failure medication and selective pulmonary vasodilator for 6 months. Post-treatment, pulmonary artery systolic pressure was significantly lower (TR Vmax 2.31 m/s, TR Max PG 21 mmHg, estimated PAP 24 mmHg). In this case, clinical evaluation, CXR, ECG, echocardiography, and cardiac catheterization data were presented with a review of the current guidelines regarding the management of paediatric patients with PAH associated with PDA.
Summary: TCC of PDA is an option to treat pulmonary hypertension in PDA patients. Combined use of drugs and TCC PDA proves beneficially synergistic effect with better outcomes and may reduce mortality.
References
2. Philip R, Lamba V, Talati A, Sathanandam S. Pulmonary Hypertension with Prolonged Patency of the Ductus Arteriosus in Preterm Infants. Child (Basel, Switzerland). 2020;7(9):139. Available from: https://pubmed.ncbi.nlm.nih.gov/32947808
3. Lammers AE, Bauer LJ, Diller G-P, Helm PC, Abdul-Khaliq H, Bauer UMM, et al. Pulmonary hypertension after shunt closure in patients with simple congenital heart defects. Int J Cardiol. 2020;308:28–32. Available from: http://dx.doi.org/10.1016/j.ijcard.2019.12.070
4. Niu MC, Mallory GB, Justino H, Ruiz FE, Petit CJ. Treatment of Severe Pulmonary Hypertension in the Setting of the Large Patent Ductus Arteriosus. Pediatrics. 2013;131(5):e1643–9. Available from: http://dx.doi.org/10.1542/peds.2011-1417
5. Brida M, Gatzoulis MA. Pulmonary arterial hypertension in adult congenital heart disease. Heart. 2018;104(19):1568–74. Available from: http://dx.doi.org/10.1136/heartjnl-2017-312106
6. Chinawa JM, Chukwu BF, Chinawa AT, Duru CO. The effects of ductal size on the severity of pulmonary hypertension in children with patent ductus arteriosus (PDA): a multi-center study. BMC Pulm Med. 2021;21(1):79. Available from: https://pubmed.ncbi.nlm.nih.gov/33663433
7. Alakhfash AA, Alqwaiee A, Alakhfash GA, Alhajjaj A, Almesned AA. Pulmonary hypertension associated with congenital heart disease; clinical decision scenario. Respir Med case reports. 2020;31:101286. Available from: https://pubmed.ncbi.nlm.nih.gov/33294357
8. Pascall E, Tulloh RM. Pulmonary hypertension in congenital heart disease. Future Cardiol. 2018/05/24. 2018;14(4):343–53. Available from: https://pubmed.ncbi.nlm.nih.gov/29792339
9. Galiè N, Humbert M, Vachiery J-L, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2015;37(1):67–119. Available from: http://dx.doi.org/10.1093/eurheartj/ehv317
10. Philip R, Nathaniel Johnson J, Naik R, Kimura D, Boston U, Chilakala S, et al. Effect of patent ductus arteriosus on pulmonary vascular disease. Congenit Heart Dis. 2019;14(1):37–41. Available from: http://dx.doi.org/10.1111/chd.12702
11. Chemla D, Humbert M, Sitbon O, Montani D, Hervé P. Systolic and Mean Pulmonary Artery Pressures. Chest. 2015;147(4):943–50. Available from: http://dx.doi.org/10.1378/chest.14-1755
12. Maya S, Gunawijaya E, Yantie NPVK, Windiani IGAT. Growth, Development, and Quality of Life in Children with Congenital Heart Disease Children. Open Access Maced J Med Sci. 2020;8(B):602–7. Available from: http://dx.doi.org/10.3889/oamjms.2020.4047
13. Nattel SN, Adrianzen L, Kessler EC, Andelfinger G, Dehaes M, Côté-Corriveau G, et al. Congenital Heart Disease and Neurodevelopment: Clinical Manifestations, Genetics, Mechanisms, and Implications. Can J Cardiol. 2017;33(12):1543–55. Available from: http://dx.doi.org/10.1016/j.cjca.2017.09.020
14. Hansmann G, Koestenberger M, Alastalo T-P, Apitz C, Austin ED, Bonnet D, et al. 2019 updated consensus statement on the diagnosis and treatment of pediatric pulmonary hypertension: The European Pediatric Pulmonary Vascular Disease Network (EPPVDN), endorsed by AEPC, ESPR and ISHLT. J Hear Lung Transplant. 2019;38(9):879–901. Available from: http://dx.doi.org/10.1016/j.healun.2019.06.022
15. Abman SH, Hansmann G, Archer SL, Ivy DD, Adatia I, Chung WK, et al. Pediatric Pulmonary Hypertension. Circulation. 2015;132(21):2037–99. Available from: http://dx.doi.org/10.1161/cir.0000000000000329
16. Mehta S, Vachiéry J-L. Pulmonary hypertension: the importance of correctly diagnosing the cause. Eur Respir Rev. 2016;25(142):372–80. Available from: https://pubmed.ncbi.nlm.nih.gov/27903659
17. Baumgartner H, De Backer J, Babu-Narayan S V, Budts W, Chessa M, Diller G-P, et al. 2020 ESC Guidelines for the management of adult congenital heart disease: the Task Force for the management of adult congenital heart disease of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Adult Congenital Heart Disease (ISACHD). Eur Heart J. 2021;42(6):563–645.
18. Liew N, Rashid Z, Tulloh R. Strategies for the management of pulmonary arterial hypertension in patients with congenital heart disease. J Congenit Cardiol. 2020;4(S1). Available from: http://dx.doi.org/10.1186/s40949-020-00052-w
19. Kuntartiwi D, Yanuarso PB, Sastroasmoro S. Sildenafil for pulmonary hypertension due to left-toright shunt after corrective procedure. Paediatr Indones. 2015;55(5):257. Available from: http://dx.doi.org/10.14238/pi55.5.2015.257-62
20. Bhalgat PS, Pinto R, Dalvi B V. Transcatheter closure of large patent ductus arteriosus with severe pulmonary arterial hypertension: Short and intermediate term results. Ann Pediatr Cardiol. 2012;5(2):135–40. Available from: https://pubmed.ncbi.nlm.nih.gov/23129901
21. Humbert M, Sitbon O, Simonneau G. Treatment of Pulmonary Arterial Hypertension. N Engl J Med. 2004;351(14):1425–36. Available from: http://dx.doi.org/10.1056/nejmra040291